Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function

European Journal of Clinical Pharmacology

Volumn 53, Issue 6, 1998, Pages 429-435

  Jonsson A ^a,b   Rydberg, T ^c   Sterner, G ^b   Melander, A ^c  

^a RYHOV COUNTY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Network for Pharmacoepidemiology Foundation   (Sweden)

Author keywords

Glibenclamide; Kidney disease

Indexed keywords

GLIBENCLAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CLINICAL ARTICLE; DIABETES MELLITUS; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0031968686     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050403     Document Type: Article

References (31)

1. Peart GF, Boutagy J, Shenfield GM (1989) The metabolism of glyburide in subjects of known debrisoquine phenotype. Clin Pharmacol Ther 45: 277-284
2. Dahl-Puustinen M-L, Alm C. Bertilsson L, Christenson I, Östman J, Thunberg E, Wikström I (1990) Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes. Br J Clin Pharmacol 30: 476-480
3. Rydberg T, Jönsson A, Melander A (1995) Comparison of the kinetics of glyburide and its active metabolites in humans. J Clin Pharm Ther 20: 283-295
4. Heptner W, Christ O, Kellner H-M, Rupp W (1969) Pharmacokinetics of a new highly effective hypoglycemic sulfonylurea derivative. Acta Diabet Lat 6 [Suppl 1]: 105-115
5. Rydberg T, Wåhlin-Boll E, Melander A (1991) Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography. J Chromatogr 564: 223-233
6. Jönsson A, Rydberg T, Ekberg G, Hallengren B, Melander A (1994) Slow elimination of glyburide in NIDDM subjects. Diabetes Care 17: 142-145
7. Rydberg T, Jönsson A, Røder M, Melander A (1994) Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 17: 1026-1030
8. Rydberg T, Jönsson A, Melander A (1997) Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 43: 373-381
9. Asplund K, Wiholm BE, Lithner F (1983) Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 24: 412-417
10. Seltzer HS (1989) Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin North Am 18: 163-183
11. Balant L (1981) Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs. Clin Pharmacokinet 6: 215-241
12. Balant L, Zahnd G, Petitpierre B, Fahre J (1973) Influence of renal failure on the pharmacokinetics and hypoglycemic effect of 3 sulfonylureas. Diabetologia 9 [Suppl]: 59
13. Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J (1973) Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia 9 [Suppl]: 331-338
14. Pearson JG, Antal EJ, Raehl CL, Gorsch HK, Craig WA, Albert KS, Welling PG (1986) Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function. Clin Pharmacol Ther 39: 318-324
15. Behrle M (1980) Untersuchungen zur Pharmakokinetik von Glibenclamid bei Nierengesunden und Niereninsuffizienten Diabetikern. PhD thesis. Ruprecht-Karl-Universität, Heidelberg, Germany
16. Jacobsson L (1983) A method for the calculation of renal clearance based on a single plasma sample. Clin Physiol 3: 297
17. Frennby B (1997) Use of iohexol to determine glomerular filtration rate. A comparison between different clearance techniques in man and animal. Scand J Urol Nephrol 31 (Suppl 182): 25-26
18. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
19. Sterner G, Frennby B, Hultberg B, Almén T (1996) Iohexol clearance for GFR-determination in renal failure - single or multiple plasma sampling? Nephrol Dial Transpl 11: 521-525
20. Krutzén E, Bäck SE, Nilsson-Ehle I, Nilsson-Ehle P (1984) Plasma clearance of a new contrast agent, iohexol; a method for the assessment of glomerular filtration rate. J Lab Clin Med 104: 955-961
21. Boxenbaum HG, Riegelman S, Elashoff RM (1974) Statistical estimations in pharmacokinetics. J Pharmacokinet Biopharm 2: 123-148
22. Wagner JG (1993) Measures of fit. In: Wagner JG (ed) Pharmacokinetics for the pharmaceutical scientist. Technomic Publishing Co., Lancaster, Pa pp 293-298
23. Imbimbo BP, Imbimbo E, Daniotti S, Verotta D, Bassotti G (1988) A new criterion for selection of pharmacokinetic multiexponential equations. J Pharm Sci 77: 784-789
24. Olsen KM, Kearns GL, Kemp SF (1995) Glyburide protein binding and the effect of albumin glycation in children, young adults and older adults with diabetes. J Clin Pharmacol 35: 739-745
25. Hedman A (1991) Biliary excretion interactions with digoxin in man. PhD thesis. Karolinska Institute, Stockholm, Sweden
26. Harrower ADB (1996) Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 31: 111-119
27. Kubacka RT, Antal EJ, Juhl RP, Welshman IR (1996) Effects of aspirin and ibuprofen on the pharmacokinetics and pharmacodynamics of glyburide in healthy subjects. Ann Pharmacother 30: 20-26
28. Scheen AJ, Lefebvre PJ (1995) Antihyperglycaemic agents. Drus interactions of clinical importance. Drug Safety 12: 32-45
29. Jaber LA, Antal EJ, Slaughter RL, Welshman IR (1994) Comparison of pharmacokinetics and pharmacodynamics of short- and long-term glyburide therapy in NIDDM. Diabetes Care 11: 1300-1306
30. Verbeeck RK, Branch RA, Wilkinson GR (1981) Drug metabolites in renal failure: pharmacokinetic and clinical implications. Clin Pharmacokinet 6: 329-345
31. Yamao T, Nakagami H, Furahama K, Onodera T, Kurosaki Y, Nakayama T, Kimura T (1994) Pharmacokinetics of tolbutamide following intravenous and oral administration in rats with obstructive jaundice. Biol Pharm Bull 17: 691-695